Home / Health / Semaglutide Fails Alzheimer's Trials
Semaglutide Fails Alzheimer's Trials
20 Mar
Summary
- Oral semaglutide showed no clinical efficacy in early Alzheimer's patients.
- Key trial endpoints for cognition and function were not met.
- Biomarker reduction was minimal and deemed clinically insignificant.
On March 19, 2026, Novo Nordisk presented disappointing full data from the EVOKE and EVOKE+ trials, revealing oral semaglutide's lack of clinical efficacy for early Alzheimer's disease. The trials showed no difference between the drug and placebo in cognitive or functional endpoints after 104 weeks. Biomarker reductions were observed but deemed clinically insignificant.
Despite prior real-world evidence suggesting benefits in metabolic conditions, the trials focused on patients with confirmed Alzheimer's pathology. This distinction, along with differing endpoints, may explain the negative results. Novo Nordisk discontinued the one-year extension periods and terminated the program in November 2025.
Panellists at the AD/PD 2026 conference suggested further research into GLP-1RAs for specific patient populations, such as those with comorbid metabolic disorders, or as preventive therapy. However, significant investment will be needed for future trials following this high-profile failure.
